Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Retrieved on: 2025-01-09 15:36:29

Tags for this article:

Click the tags to see associated articles and topics

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS. View article details on hiswai:

Excerpt

PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, ...

Article found on: www.prnewswire.com